Boston Partners Purchases 29,394 Shares of DaVita Inc. (NYSE:DVA)

Boston Partners increased its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 48.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 89,453 shares of the company's stock after acquiring an additional 29,394 shares during the quarter. Boston Partners owned about 0.11% of DaVita worth $13,387,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in DVA. SBI Securities Co. Ltd. purchased a new position in shares of DaVita during the fourth quarter worth $41,000. Quarry LP acquired a new position in DaVita in the third quarter valued at approximately $60,000. Venturi Wealth Management LLC grew its position in shares of DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after buying an additional 152 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after purchasing an additional 169 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after buying an additional 131 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on DVA shares. Barclays upped their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. StockNews.com downgraded shares of DaVita from a "buy" rating to a "hold" rating in a research report on Friday. Finally, Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $166.33.

Remove Ads

DaVita Stock Up 1.6 %

NYSE:DVA traded up $2.41 during trading hours on Monday, reaching $150.56. The company's stock had a trading volume of 704,916 shares, compared to its average volume of 783,786. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business's 50-day moving average is $158.40 and its 200-day moving average is $157.57. The company has a market cap of $12.04 billion, a price-to-earnings ratio of 14.02, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.